Effect of the Insulin Sensitizer Pioglitazone on Insulin Resistance, Hyperandrogenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, chronic anovulation, and insulin resistance; long-term consequences include diabetes mellitus type 2. The aim of this randomized, double-blind, controlled trial was to investigate whether the thiazolidinedione derivative pioglitazone diminishes insulin resistance and hyperandrogenism and enhances ovulation rates in women with PCOS. Forty premenopausal women with PCOS were randomly allocated to treatment with either pioglitazone (30 mg/d) or placebo for periods of 3 months. Administration of pioglitazone resulted in a remarkable decline in both fasting serum insulin levels (P < 0.02) and the area under the insulin response curve after an oral glucose load (P < 0.02). This represented an increase in insulin sensitivity and a decrease in insulin secretion (P < 0.05). Furthermore, pioglitazone increased serum SHBG (P < 0.05), resulting in a significant decrease in the free androgen index (P < 0.05 compared with placebo). Treatment with pioglitazone was also associated with higher ovulation rates (P < 0.02). Thus, pioglitazone significantly improved insulin sensitivity, hyperandrogenism, and ovulation rates in women with PCOS, thereby providing both metabolic and reproductive benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428 · cited 1×
“The long-term consequences are similar to those of the metabolic syndrome, including an elevated risk for myocardial infarction (4–6), diabetes mellitus (7, 8), endothelial dysfunction, hemostatic abnormalities, hypertension, and dyslipidemia (9).”
BackgroundCostello, M. F., & Eden, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04554-5 · Cited by 224 · cited 2×
“muscle) (32), has also been assessed in women with PCOS.”
BackgroundTroglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195 · cited 1×
“Meanwhile, due to significant hepatic toxicity, troglitazone, the only compound that has been tested in prospective controlled trials, has been withdrawn from the market (24, 25).”
BackgroundArlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157 · cited 1×
“Thiazolidinediones may have androgen-lowering effects due to inhibition of P450c17 and 3 -hydroxysteroid dehydrogenase, two key enzymes in human androgen synthesis (37).”
Background
Cited by
Franks, S. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.1.89 · Cited by 806
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Abbott, D. H., Barnett, D. K., Bruns, C. M., & Dumesic, D. A. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi013 · Cited by 555
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
Diet and Lifestyle in the Prevention of Ovulatory Disorder Infertility
Chavarro, J. E., Rich-Edwards, J. W., Rosner, B. A., & Willett, W. C. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000287293.25465.e1 · Cited by 442
Insulin and hyperandrogenism in women with polycystic ovary syndrome
Baptiste, C. G., Battista, M.-C., Trottier, A., & Baillargeon, J.-P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.12.010 · Cited by 355
Poly Cystic Ovarian Syndrome: An Updated Overview
El Hayek, S., Bitar, L., Hamdar, L. H., Mirza, F. G., & Daoud, G. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00124 · Cited by 323
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Polycystic ovary syndrome and its developmental origins
Dumesic, D. A., Abbott, D. H., & Padmanabhan, V. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9046-0 · Cited by 283
Rachoń, D., & Teede, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.026 · Cited by 161
“Limited studies have looked at pioglitazone, which reduces serum insulin and androgens, and may restore menstrual cyclicity and ovulation in women with PCOS (Brettenthaler et al., 2004).”
BackgroundOvulation induction: a mini review
Messinis, I. E. (2005) · Human Reproduction · doi:10.1093/humrep/dei128 · Cited by 140
“, 2003), while a recent randomized controlled trial has shown that pioglitazone increased ovulation rate as compared to placebo (Brettenthaler et al., 2004).”
BackgroundResultThe management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Lu, C., Cardoso, R. C., Puttabyatappa, M., & Padmanabhan, V. (2016) · Biology of Reproduction · doi:10.1095/biolreprod.115.136283 · Cited by 40
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Metformin before and during pregnancy and lactation in polycystic ovary syndrome
Glueck, C. J., & Wang, P. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.2.191 · Cited by 36
Zuuren, E. J., & Fedorowicz, Z. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14486 · Cited by 35
BERRIA, R., GASTALDELLI, A., LUCIDI, S., BELFORT, R., DEFILIPPIS, E., EASTON, C., BRYTZKI, R., CUSI, K., JOVANOVIC, L., & DEFRONZO, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.014 · Cited by 33
Amini, L., Mojab, F., Jahanfar, S., Sepidarkish, M., Raoofi, Z., & Maleki-Hajiagha, A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102245 · Cited by 30
Interventions for the metabolic dysfunction in polycystic ovary syndrome
Bozdag, G., & Yildiz, B. O. (2013) · Steroids · doi:10.1016/j.steroids.2013.04.008 · Cited by 18
“In 2 trials of 70 women [27,28], pioglitazone did not significantly change BMI, WHR or any of the metabolic parameters.”
Background
Metadata
- Authors
- Brettenthaler, N., De Geyter, C., Huber, P. R., & Keller, U.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-08
- Volume
- 89
- Issue
- 8
- Pages
- 3835-3840
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2147127250
- Cited by
- 247
- References
- 12
- FWCI
- 21.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.